EdgarLookup

Palo Alto Networks Inc — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Palo Alto Networks Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
49.9%
Profit Margin
Net income ÷ revenue
4.8%
Return on Assets
Net income ÷ assets
2.01x
Debt-to-Equity
Total liabilities ÷ equity
+29%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2018 Jul 31, 2018 $2.27B Sep 13, 2018
FY2018 Jul 31, 2017 $1.76B Sep 13, 2018
FY2018 Jul 31, 2016 $1.38B Sep 13, 2018
FY2017 Jul 31, 2015 $928.10M Sep 7, 2017
FY2016 Jul 31, 2014 $598.20M Sep 8, 2016
FY2015 Jul 31, 2013 $396.11M Sep 17, 2015
FY2014 Jul 31, 2012 $255.14M Sep 18, 2014
FY2013 Jul 31, 2011 $118.60M Sep 25, 2013

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $9.22B Aug 29, 2025
FY2025 Jul 31, 2024 $8.03B Aug 29, 2025
FY2025 Jul 31, 2023 $6.89B Aug 29, 2025
FY2024 Jul 31, 2022 $5.50B Sep 6, 2024
FY2023 Jul 31, 2021 $4.26B Sep 1, 2023
FY2020 Jul 31, 2020 $950.40M Sep 4, 2020
FY2020 Apr 30, 2020 $869.40M Sep 4, 2020
FY2020 Jan 31, 2020 $816.70M Sep 4, 2020
FY2020 Oct 31, 2019 $771.90M Sep 4, 2020
FY2020 Jul 31, 2019 $805.80M Sep 4, 2020

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2018 Jul 31, 2018 $658.10M Sep 13, 2018
FY2018 Apr 30, 2018 $567.10M Sep 13, 2018
FY2018 Jan 31, 2018 $542.40M Sep 13, 2018
FY2018 Oct 31, 2017 $505.50M Sep 13, 2018
FY2018 Jul 31, 2017 $509.10M Sep 13, 2018
FY2018 Apr 30, 2017 $431.80M Sep 13, 2018
FY2018 Jan 31, 2017 $422.60M Sep 13, 2018
FY2018 Oct 31, 2016 $398.10M Sep 13, 2018
FY2017 Jul 31, 2016 $400.80M Sep 7, 2017
FY2017 Apr 30, 2016 $345.80M Sep 7, 2017

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $6.77B Aug 29, 2025
FY2025 Jul 31, 2024 $5.97B Aug 29, 2025
FY2025 Jul 31, 2023 $4.98B Aug 29, 2025
FY2024 Jul 31, 2022 $3.78B Sep 6, 2024
FY2023 Jul 31, 2021 $2.98B Sep 1, 2023
FY2020 Jul 31, 2020 $660.00M Sep 4, 2020
FY2020 Apr 30, 2020 $611.10M Sep 4, 2020
FY2020 Jan 31, 2020 $583.60M Sep 4, 2020
FY2020 Oct 31, 2019 $554.20M Sep 4, 2020
FY2020 Jul 31, 2019 $588.40M Sep 4, 2020

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $1.13B Aug 29, 2025
FY2025 Jul 31, 2024 $2.58B Aug 29, 2025
FY2025 Jul 31, 2023 $439.70M Aug 29, 2025
FY2024 Jul 31, 2022 ($267.00M) Sep 6, 2024
FY2023 Jul 31, 2021 ($498.90M) Sep 1, 2023
FY2020 Jul 31, 2020 ($58.90M) Sep 4, 2020
FY2020 Apr 30, 2020 ($74.80M) Sep 4, 2020
FY2020 Jan 31, 2020 ($73.70M) Sep 4, 2020
FY2020 Oct 31, 2019 ($59.60M) Sep 4, 2020
FY2020 Jul 31, 2019 ($20.80M) Sep 4, 2020

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $1.24B Aug 29, 2025
FY2025 Jul 31, 2024 $683.90M Aug 29, 2025
FY2025 Jul 31, 2023 $387.30M Aug 29, 2025
FY2024 Jul 31, 2022 ($188.80M) Sep 6, 2024
FY2023 Jul 31, 2021 ($304.10M) Sep 1, 2023
FY2020 Jul 31, 2020 ($17.80M) Sep 4, 2020
FY2020 Apr 30, 2020 ($56.50M) Sep 4, 2020
FY2020 Jan 31, 2020 ($52.90M) Sep 4, 2020
FY2020 Oct 31, 2019 ($51.80M) Sep 4, 2020
FY2020 Jul 31, 2019 ($9.90M) Sep 4, 2020

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $1.98B Aug 29, 2025
FY2025 Jul 31, 2024 $1.81B Aug 29, 2025
FY2025 Jul 31, 2023 $1.60B Aug 29, 2025
FY2024 Jul 31, 2022 $1.42B Sep 6, 2024
FY2023 Jul 31, 2021 $1.14B Sep 1, 2023
FY2020 Jul 31, 2020 $215.90M Sep 4, 2020
FY2020 Apr 30, 2020 $196.30M Sep 4, 2020
FY2020 Jan 31, 2020 $185.40M Sep 4, 2020
FY2020 Oct 31, 2019 $170.50M Sep 4, 2020
FY2020 Jul 31, 2019 $158.70M Sep 4, 2020

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $3.72B Aug 29, 2025
FY2025 Jul 31, 2024 $3.26B Aug 29, 2025
FY2025 Jul 31, 2023 $2.78B Aug 29, 2025
FY2024 Jul 31, 2022 $1.98B Sep 6, 2024
FY2023 Jul 31, 2021 $1.50B Sep 1, 2023
FY2022 Jul 31, 2020 $1.04B Sep 6, 2022
FY2021 Jul 31, 2019 $1.06B Sep 3, 2021
FY2020 Jul 31, 2018 $1.04B Sep 4, 2020
FY2019 Jul 31, 2017 $868.80M Sep 9, 2019
FY2018 Jul 31, 2016 $658.60M Sep 13, 2018

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $23.58B Aug 29, 2025
FY2025 Jul 31, 2024 $19.99B Aug 29, 2025
FY2024 Jul 31, 2023 $14.50B Sep 6, 2024
FY2023 Jul 31, 2022 $12.25B Sep 1, 2023
FY2022 Jul 31, 2021 $10.24B Sep 6, 2022
FY2021 Jul 31, 2020 $9.07B Sep 3, 2021
FY2020 Jul 31, 2019 $6.59B Sep 4, 2020
FY2019 Jul 31, 2018 $5.95B Sep 9, 2019
FY2018 Jul 31, 2017 $3.44B Sep 13, 2018
FY2017 Jul 31, 2016 $2.86B Sep 7, 2017

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $15.75B Aug 29, 2025
FY2025 Jul 31, 2024 $14.82B Aug 29, 2025
FY2024 Jul 31, 2023 $12.75B Sep 6, 2024
FY2023 Jul 31, 2022 $12.04B Sep 1, 2023
FY2022 Jul 31, 2021 $9.48B Sep 6, 2022

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $7.82B Aug 29, 2025
FY2025 Jul 31, 2024 $5.17B Aug 29, 2025
FY2025 Jul 31, 2023 $1.75B Aug 29, 2025
FY2025 Jul 31, 2022 $210.00M Aug 29, 2025
FY2024 Jul 31, 2021 $634.50M Sep 6, 2024
FY2021 Jul 31, 2020 $1.10B Sep 3, 2021
FY2020 Jul 31, 2019 $1.59B Sep 4, 2020
FY2019 Jul 31, 2018 $1.16B Sep 9, 2019
FY2018 Jul 31, 2017 $759.60M Sep 13, 2018
FY2017 Jul 31, 2016 $894.90M Sep 7, 2017

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $4.57B Aug 29, 2025
FY2025 Jul 31, 2024 $3.35B Aug 29, 2025
FY2024 Jul 31, 2023 $2.93B Sep 6, 2024
FY2023 Jul 31, 2022 $2.75B Sep 1, 2023
FY2022 Jul 31, 2021 $2.71B Sep 6, 2022
FY2021 Jul 31, 2020 $1.81B Sep 3, 2021
FY2020 Jul 31, 2019 $1.35B Sep 4, 2020
FY2019 Jul 31, 2018 $522.80M Sep 9, 2019
FY2018 Jul 31, 2017 $238.80M Sep 13, 2018
FY2017 Jul 31, 2016 $163.50M Sep 7, 2017

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $2.48B Aug 29, 2025
FY2025 Jul 31, 2024 $1.35B Aug 29, 2025
FY2024 Jul 31, 2023 ($1.23B) Sep 6, 2024
FY2023 Jul 31, 2022 ($1.67B) Sep 1, 2023
FY2022 Jul 31, 2021 ($1.67B) Sep 6, 2022
FY2021 Jul 31, 2020 ($1.17B) Sep 3, 2021
FY2020 Jul 31, 2019 ($900.90M) Sep 4, 2020
FY2019 Jul 31, 2018 ($790.70M) Sep 9, 2019
FY2018 Jul 31, 2017 ($836.70M) Sep 13, 2018
FY2017 Jul 31, 2016 ($621.60M) Sep 7, 2017

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $2.27B Aug 29, 2025
FY2025 Jul 31, 2024 $1.54B Aug 29, 2025
FY2025 Jul 31, 2023 $1.14B Aug 29, 2025
FY2024 Jul 31, 2022 $2.12B Sep 6, 2024
FY2023 Jul 31, 2021 $1.87B Sep 1, 2023
FY2022 Jul 31, 2020 $2.96B Sep 6, 2022
FY2021 Jul 31, 2019 $961.40M Sep 3, 2021
FY2020 Jul 31, 2018 $2.51B Sep 4, 2020
FY2019 Jul 31, 2017 $744.30M Sep 9, 2019
FY2018 Jul 31, 2016 $734.40M Sep 13, 2018

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2023 Jul 31, 2023 $1.99B Sep 1, 2023
FY2023 Jul 31, 2022 $3.68B Sep 1, 2023
FY2022 Jul 31, 2021 $3.23B Sep 6, 2022
FY2021 Jul 31, 2020 $3.08B Sep 3, 2021
FY2020 Jul 31, 2019 $1.43B Sep 4, 2020
FY2019 Jul 31, 2018 $1.92B Sep 9, 2019
FY2018 Jul 31, 2017 $524.70M Sep 13, 2018
FY2017 Jul 31, 2016 $500.20M Sep 7, 2017
FY2016 Jul 31, 2015 $487.10M Sep 8, 2016
FY2015 Jul 31, 2014 $466.88M Sep 17, 2015

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 1 Aug 29, 2025
FY2025 Jul 31, 2024 4 Aug 29, 2025
FY2025 Jul 31, 2023 0 Aug 29, 2025
FY2024 Jul 31, 2022 0 Sep 6, 2024
FY2023 Jul 31, 2021 (1) Sep 1, 2023
FY2022 Jul 31, 2020 (2) Sep 6, 2022
FY2021 Jul 31, 2019 0 Sep 3, 2021
FY2019 Jul 31, 2018 0 Sep 9, 2019
FY2019 Apr 30, 2018 0 Sep 9, 2019
FY2019 Jan 31, 2018 0 Sep 9, 2019

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 1 Aug 29, 2025
FY2025 Jul 31, 2024 3 Aug 29, 2025
FY2025 Jul 31, 2023 0 Aug 29, 2025
FY2024 Jul 31, 2022 0 Sep 6, 2024
FY2023 Jul 31, 2021 (1) Sep 1, 2023
FY2022 Jul 31, 2020 (2) Sep 6, 2022
FY2021 Jul 31, 2019 0 Sep 3, 2021
FY2019 Jul 31, 2018 0 Sep 9, 2019
FY2019 Apr 30, 2018 0 Sep 9, 2019
FY2019 Jan 31, 2018 0 Sep 9, 2019

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 667.90M Aug 29, 2025
FY2025 Jul 31, 2024 650.20M Aug 29, 2025
FY2024 Jul 31, 2023 308.30M Sep 6, 2024
FY2023 Jul 31, 2022 298.80M Sep 1, 2023
FY2022 Jul 31, 2021 97.30M Sep 6, 2022
FY2021 Jul 31, 2020 96.30M Sep 3, 2021
FY2020 Jul 31, 2019 96.80M Sep 4, 2020
FY2019 Jul 31, 2018 93.60M Sep 9, 2019
FY2018 Jul 31, 2017 91.50M Sep 13, 2018
FY2017 Jul 31, 2016 90.50M Sep 7, 2017